<DOC>
	<DOCNO>NCT02139215</DOCNO>
	<brief_summary>This phase IV multicenter trial evaluate real-world health outcome economic impact panitumumab versus standard-of-care ( SOC ) treatment patient chemotherapy-refractory metastatic colorectal cancer ( mCRC ) . The study enable real-life health economics outcome research ( HEOR ) ass impact panitumumab Quebec population . The primary objective evaluate real-world health outcome economic impact panitumumab treatment patient chemotherapy-refractory mCRC comparison SOC . The secondary objective confirm survival data , ass quality life patient assess health care resource utilization patient . Patients mutate KRAS gene treat standard-of-care ( SOC ) patient non-mutated ( wild type ) KRAS gene treat panitumumab . During course study , data collect quality life work productivity . Patients ask fill set questionnaire recruitment study every 3 month treatment initiation .</brief_summary>
	<brief_title>Study Evaluate Real-world Pharmacoeconomics Panitumumab Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients histologically confirm diagnosis mCRC . Immunohistochemical evidence EGFR expression . ECOG performance status 0 , 1 2 . Patients refractory fluoropyrimidine , oxaliplatin , irinotecan chemotherapy regimens Patients wt KRAS schedule receive panitumumab single agent thirdline treatment mCRC patient mt KRAS schedule receive SOC thirdline treatment mCRC . Signed date IRBapproved inform consent document . Ability read understand English French . 18 year age old .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>